pIn the United States, a rare disease is defined by the Orphan Drug Act as a disorder or condition that affects fewer than 200,000 persons. For the approval of orphan drug products for rare diseases, the traditional approach of power analysis for sample size calculation is not feasible because there are only limited number of subjects available for clinical trials. In this case, innovative approaches are needed for providing substantial evidence meeting the same standards for statistical assurance as drugs used to treat common conditions. biInnovative Methods for Rare Disease Drug Developmentibi ifocuses on biostatistical applications in terms of design and analysis in pharmaceutical research and development from both regulatory and scientific statistical perspectives. ppKey Features pul p p liReviews critical issues e.g., endpointmargin selection, sample size requirements, and complex innovative design.li p p liProvides better understanding of statistical concepts and methods which ma